Kenichi Tanaka

Kenichi Tanaka

Auto-generated profile, based on publicly available information

Kenichi Tanaka

First Department of Internal Medicine, School of Medicine University of Occupational and Environmental Health Kitakyushu Japan

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Bone
Verified
Journal Article
Closed access
KTKenichi Tanaka
Kenichi Tanaka
KYKaoru Yamagata
Kaoru Yamagata
SKSatoshi Kubo
Satoshi Kubo
SNShingo Nakayamada
Shingo Nakayamada
KSKei Sakata
Kei Sakata
Yoshiya TanakaYoshiya Tanaka
Yoshiya Tanaka

1 July 2006 in Journal of Controlled Release
Verified
Journal Article
Closed access
TSTakehiro Serikawa
Takehiro Serikawa
AKAkira Kikuchi
Akira Kikuchi
SSSusumu Sugaya
Susumu Sugaya
NSNorio Suzuki
Norio Suzuki
HKHiroshi Kikuchi
Hiroshi Kikuchi
KTKenichi Tanaka
Kenichi Tanaka

1 March 2004 in Journal of Bone and Mineral Metabolism
Verified
Journal Article
Closed access
PDF file
TKTakumi Kurabayashi
Takumi Kurabayashi
HMHiroshi Matsushita
Hiroshi Matsushita
NKNozomi Kato
Nozomi Kato
HNHiroshi Nagata
Hiroshi Nagata
MKMariko Kikuchi
Mariko Kikuchi
KTKenichi Tanaka
Kenichi Tanaka

20 January 1996 in Human Gene Therapy
Verified
Journal Article
Closed access
SSSusumu Sugaya
Susumu Sugaya
KFKazuyuki Fujita
Kazuyuki Fujita
AKAkira Kikuchi
Akira Kikuchi
HUHiroyuki Ueda
Hiroyuki Ueda
KTKoichi Takakuwa
Koichi Takakuwa
KTKenichi Tanaka
Kenichi Tanaka
To establish the expression of the herpes simplex virus thymidine kinase (HSV-TK) gene in tumor cells, we analyzed the promoter function of the SV40 promoter and the nucleotide sequence (CACGTG) to which Myc-Max heterodimers (Myc/Max) were capable of binding in four kinds of cell lines: COLO320 DM, A-431, KF, and Nakajima. When luciferase reporter plasmid under the control of SV40 promoter was transfected into tumor cells in vitro, a high level of luciferase activity was observed in all kinds of cell lines. However, by transfection of the luciferase gene promoted by the Myc/Max binding sequence, accelerated luciferase expression was observed in COLO320 DM and A-431 cells with high expression of c-myc, but not in KF and Nakajima cells, which showed low expression of c-myc. The repeated transfection of the liposome-conjugated HSV-TK gene regulated by the SV40 promoter and cultivation in 100 micrograms/ml of aciclovir for 5 days in vitro demonstrated growth inhibition for all four kinds of cell lines. However, cell toxicity was observed only in COLO320 DM and A-431 cells when the HSV-TK gene promoted by the Myc/Max binding sequence was introduced. (The survival rate to 100 micrograms/ml of aciclovir concentration in COLO320 DM, A-431, KF, and Nakajima cells was 59%, 53%, 74%, and 79%, respectively.) In vivo direct injection of the liposome-conjugated HSV-TK gene regulated by the SV40 promoter into established tumors and aciclovir administration for 10 days into the mice resulted in significant tumor volume reduction in three tested tumor cells. However, injection of the HSV-TK gene promoted by the Myc/Max binding sequence and aciclovir administration into mice could achieve significant tumor regression only in COLO320 DM and A-431 cells. These results suggest that gene therapy using the HSV-TK gene promoted by the Myc/Max binding sequence can be an attractive approach for treatment against tumor cells expressing high levels of c-myc.

1 January 1996 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
SKShoji Kodama
Shoji Kodama
HKHiroaki Kase
Hiroaki Kase
YAYouich Aoki
Youich Aoki
TYTetsuro Yahata
Tetsuro Yahata
KTKenichi Tanaka
Kenichi Tanaka
KDKohji Dewa
Kohji Dewa

23 July 2020 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
PDF file
KTKenichi Tanaka
Kenichi Tanaka
YOYosuke Okada
Yosuke Okada
HMHajime Maiko
Hajime Maiko
HMHiroko Mori
Hiroko Mori
YTYoshiya Tanaka
Yoshiya Tanaka
Aims/Introduction: There are limited reports on the association between melatonin levels and vascular complications in patients with type 2 diabetes. The aim of this study was to determine the association between urinary 6‐sulfatoxymelatonin, which is a urinary metabolite of melatonin, and diabetic vascular complications or arteriosclerosis in patients with type 2 diabetes.Materials and Methods: This retrospective study included patients (167 patients with type 2 diabetes and 27 patients without diabetes adjusted for age and sex) admitted to the hospital who underwent measurement of urinary 6‐sulfatoxymelatonin. The urinary 6‐sulfatoxymelatonin/creatinine ratio (6‐SMT) was calculated.Results: The natural logarithmically scaled 6‐SMT level (Ln 6‐SMT) was significantly lower in type 2 diabetes patients (1.9 ± 1.1) compared with patients without diabetes (2.8 ± 1.0, P < 0.001). Multivariate linear regression analysis identified duration of diabetes, smoking status, urinary albumin‐to‐creatinine ratio, retinopathy and coronary heart disease as factors that could influence Ln 6‐SMT levels in type 2 diabetes patients (R2 = 0.232, P < 0.001). Ln 6‐SMT was associated with decreased odds of diabetic retinopathy, even after adjustment for various confounding factors (odds ratio 0.559, 95% confidence interval 0.369–0.846, P = 0.006). Similarly, Ln 6‐SMT was associated with decreased odds of coronary heart disease (odds ratio 0.442, P = 0.030).Conclusions: Our results showed the presence of low levels of Ln 6‐SMT in type 2 diabetes patients relative to patients without diabetes. Furthermore, Ln 6‐SMT is an independent risk factor of diabetic retinopathy and coronary heart diseases. These findings suggest that 6‐SMT could be a useful biomarker for the prediction of micro‐ and macrovasculopathies in patients with type 2 diabetes.